# Moderate iron deficiency and high dietary iron intake differentially alter hepatic lipid metabolism and adipose tissue lipid handling in mice

**Authors:** Shangjie Wu, Pengwei Li, Qian Liu, Keying Zhang, Xuemei Ding, Jianping Wang, Qiufeng Zeng, Yan Liu, Yue Xuan, Shanshan Li, Yadong Mu, Shiping Bai

PMC · DOI: 10.3389/fnut.2025.1725052 · Frontiers in Nutrition · 2026-01-27

## TL;DR

This study shows that both low and high iron levels in mice disrupt liver lipid metabolism through different mechanisms, highlighting the importance of maintaining iron balance for metabolic health.

## Contribution

The study reveals distinct molecular pathways by which moderate iron deficiency and high iron intake affect hepatic lipid metabolism in mice.

## Key findings

- Moderate iron deficiency increased lipolysis in adipose tissue and altered hepatic gene expression without increasing triglycerides.
- High dietary iron caused hyperlipidemia and hepatic iron overload via activation of lipogenic pathways and increased hepcidin expression.
- Both iron deficiency and overload altered hepatic fatty acid composition but through fundamentally different mechanisms.

## Abstract

Iron (Fe) is an essential micronutrient, yet both its deficiency and overload have been associated with disruptions in lipid metabolism. This study investigated the effects of moderate iron deficiency and high dietary iron on lipid metabolic pathways in mice.

Five-week male C57BL/6J mice were fed for 16 weeks on one of three diets: a basal iron-deficient diet without iron supplementation (FeD, 19.26 mg/kg Fe), and the same basal diet supplemented with either 200 mg Fe/kg (iron-adequate control, Control) or 1,200 mg Fe/kg (high-iron, FeH). Growth performance, iron status, serum lipids, tissue iron deposition, hepatic fatty acid composition, and expression of key genes and enzymes involved in lipid metabolism were analyzed.

The FeD group exhibited increased body weight and feed intake, and reduced systemic iron parameters. Molecular analysis revealed a distinct pattern of lipid metabolic disruption in FeD, characterized by the upregulation of certain hepatic lipogenic transcripts (ACLY, SREBP1c, PPARγ) but without a concomitant increase in functional lipogenic output or hepatic triglycerides. Notably, the elevation in SCD1 protein occurred alongside a decreased hepatic C18:1 n-9/C18:0 ratio in the FeD group. In adipose tissue, FeD specifically enhanced lipolysis gene expression (ATGL, HSL, FABP4), indicating elevated lipid mobilization. In contrast, FeH mice developed hyperlipidemia and hepatic iron overload, which was driven by direct activation of the hepatic SREBP1c pathway and its lipogenic targets (ACC, FAS, SCD1). Hamp expression was significantly upregulated in the FeH group compared to both the control and FeD groups (p < 0.05). Although both diets altered hepatic fatty acid composition, they operated through fundamentally distinct mechanisms.

These findings demonstrate that moderate iron deficiency and high iron intake disrupt hepatic lipid metabolism via different pathways: FeD primarily through systemic adaptations leading to post-translational constraints on iron-dependent enzymes, whereas FeH acts through direct transcriptional activation of hepatic de novo lipogenesis, potentially involving hepcidin-mediated cross-talk. The study underscores the critical importance of iron homeostasis in preventing dyslipidemia and hepatic steatosis and provides mechanistic insights that could inform dietary recommendations for populations at risk of metabolic disorders.

## Linked entities

- **Genes:** ACLY (ATP citrate lyase) [NCBI Gene 47], Srebf1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 78968], PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468], SCD (stearoyl-CoA desaturase) [NCBI Gene 6319], PNPLA2 (patatin like domain 2, triacylglycerol lipase) [NCBI Gene 57104], LIPE (lipase E, hormone sensitive type) [NCBI Gene 3991], FABP4 (fatty acid binding protein 4) [NCBI Gene 2167], ACACA (acetyl-CoA carboxylase alpha) [NCBI Gene 31], FAS (Fas cell surface death receptor) [NCBI Gene 355], HAMP (hepcidin antimicrobial peptide) [NCBI Gene 57817]

## Full-text entities

- **Genes:** Pparg (peroxisome proliferator activated receptor gamma) [NCBI Gene 19016] {aka Nr1c3, PPAR-gamma, PPAR-gamma2, PPARgamma, PPARgamma2}, Fabp4 (fatty acid binding protein 4, adipocyte) [NCBI Gene 11770] {aka 422/aP2, AFABP, ALBP, ALBP/Ap2, Ap2, Lbpl}, Srebf1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 20787] {aka ADD1, SREBP1, bHLHd1}, Acly (ATP citrate lyase) [NCBI Gene 104112] {aka A730098H14Rik}, Hamp (hepcidin antimicrobial peptide) [NCBI Gene 84506] {aka Hamp1, Hepc, Hepc1}, Pnpla2 (patatin-like phospholipase domain containing 2) [NCBI Gene 66853] {aka 0610039C21Rik, 1110001C14Rik, Atgl, TTS-2.2}, Acc (anterior capsular cataract) [NCBI Gene 104371], Lipe (lipase E, hormone sensitive type) [NCBI Gene 16890] {aka 4933403G17Rik, HSL, REH}, Scd1 (stearoyl-Coenzyme A desaturase 1) [NCBI Gene 20249] {aka Scd, Scd-1, ab}
- **Diseases:** metabolic disorders (MESH:D008659), hepatic steatosis (MESH:D005234), dyslipidemia (MESH:D050171), hepatic (MESH:D056486), hyperlipidemia (MESH:D006949), iron (MESH:D000090463), iron overload (MESH:D019190)
- **Chemicals:** triglycerides (MESH:D014280), FeH (-), Fe (MESH:D007501), fatty acid (MESH:D005227), lipid (MESH:D008055)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12888867/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12888867/full.md

## References

45 references — full list in the complete paper: https://tomesphere.com/paper/PMC12888867/full.md

---
Source: https://tomesphere.com/paper/PMC12888867